Jeyaratnaganthan Nilani, Højlund Kurt, Kroustrup Jens Peter, Larsen Jens Fromholt, Bjerre Mette, Levin Klavs, Beck-Nielsen Henning, Frago Susana, Hassan A Bassim, Flyvbjerg Allan, Frystyk Jan
The Medical Research Laboratories, Clinical Institute of Medicine & Medical Department M, Aarhus University Hospital, DK-8000 Aarhus C, Denmark.
Growth Horm IGF Res. 2010 Jun;20(3):185-91. doi: 10.1016/j.ghir.2009.12.005. Epub 2010 Jan 27.
The extracellular domain of the insulin-like growth factor II/mannose-6-phosphate receptor (IGF-II/M6P-R) is present in the circulation, but its relationship with plasma IGF-II is largely unknown. As IGF-II appears to be nutritionally regulated, we studied the impact of obesity, type 2 diabetes (T2D) and weight loss on circulating levels of IGF-II and its soluble receptor.
Twenty-three morbidly obese non-diabetic subjects were studied before and after gastric banding (GB), reducing their BMI from 59.3+/-1.8 to 52.7+/-1.6 kg/m(2). Lean controls (n=10, BMI 24.2+/-0.5 kg/m(2)), moderately obese controls (n=21, BMI 31.8+/-1.0 kg/m(2)) and obese T2D patients (n=20, BMI 32.3+/-0.8 kg/m(2)) were studied before and after a hyperinsulinaemic euglycaemic clamp.
Morbidly obese subjects had elevated IGF-II/M6P-R and IGF-II levels, which both decreased following GB (IGF-II/M6P-R: from 0.97+/-0.038 to 0.87+/-0.030 nmol/l, P=0.001; IGF-II: from 134+/-7 to 125+/-6 nmol/l, P=0.01), as did fasting plasma glucose and insulin (P<0.05). However, the metabolic parameters correlated with neither IGF-II nor IGF-II/M6P-R. Obese diabetics had increased IGF-II/M6P-R as compared with lean and obese controls (0.82+/-0.031 vs. 0.70+/-0.033 vs. 0.74+/-0.026 nmol/l; P<0.03) and levels were unaffected by clamp. In the latter cohort, IGF-II/M6P-R but not IGF-II correlated with HbA1c, and fasting plasma C-peptide, insulin and glucose (0.34<r<0.45; P<0.05). In all subjects, BMI correlated with IGF-II/M6P-R (r=0.57; P<0.001) and IGF-II (r=0.39; P<0.005). IGF-II/M6P-R and IGF-II were not associated.
Serum IGF-II/M6P-R is up-regulated in morbid obesity, down-regulated by weight loss and elevated in moderately obese T2D. However, although plasma IGF-II was also reduced following GB, the two peptides were not statistically correlated. No acute effect of insulin was seen. These findings indicate that the IGF-II/M6P-R is nutritionally regulated, independently of IGF-II.
胰岛素样生长因子II/甘露糖-6-磷酸受体(IGF-II/M6P-R)的细胞外结构域存在于循环中,但其与血浆IGF-II的关系在很大程度上尚不清楚。由于IGF-II似乎受营养调节,我们研究了肥胖、2型糖尿病(T2D)和体重减轻对循环中IGF-II及其可溶性受体水平的影响。
对23名病态肥胖的非糖尿病受试者在接受胃束带术(GB)前后进行研究,其体重指数(BMI)从59.3±1.8降至52.7±1.6kg/m²。对瘦对照组(n = 10,BMI 24.2±0.5kg/m²)、中度肥胖对照组(n = 21,BMI 31.8±1.0kg/m²)和肥胖T2D患者(n = 20,BMI 32.3±0.8kg/m²)在高胰岛素正常血糖钳夹前后进行研究。
病态肥胖受试者的IGF-II/M6P-R和IGF-II水平升高,GB术后两者均降低(IGF-II/M6P-R:从0.97±0.038降至0.87±0.030nmol/l,P = 0.001;IGF-II:从134±7降至125±6nmol/l,P = 0.01),空腹血糖和胰岛素水平也降低(P<0.05)。然而,代谢参数与IGF-II和IGF-II/M6P-R均无相关性。与瘦对照组和肥胖对照组相比,肥胖糖尿病患者的IGF-II/M6P-R升高(0.82±0.031 vs. 0.70±0.033 vs. 0.74±0.026nmol/l;P<0.03),且钳夹对此水平无影响。在后者队列中,IGF-II/M6P-R与糖化血红蛋白(HbA1c)、空腹血浆C肽、胰岛素和葡萄糖相关,但IGF-II不相关(0.34<r<0.45;P<0.05)。在所有受试者中,BMI与IGF-II/M6P-R(r = 0.57;P<0.001)和IGF-II(r = 0.39;P<0.005)相关。IGF-II/M6P-R与IGF-II不相关。
血清IGF-II/M6P-R在病态肥胖中上调,体重减轻使其下调,在中度肥胖的T2D中升高。然而,尽管GB术后血浆IGF-II也降低,但这两种肽无统计学相关性。未观察到胰岛素的急性作用。这些发现表明IGF-II/M6P-R受营养调节,独立于IGF-II。